The Trump administration's denial of visas for certain countries prevents medical residents from filling critical positions in US hospitals.

Guselkumab and risankizumab for psoriasis have the highest rates of drug survival among biologics measured and a comparable safety profile.

Rates of Raynaud phenomenon medication initiation are low among patients with SSc in the United States, with less than one-third receiving consistent treatment.

Between the years 2010 and 2019, the percentage of publicly insured children with a mental health or neurodevelopmental diagnosis increased.

Among pediatric patients with AD, dermatologists more frequently prescribe treatments while allergists order more diagnostic testing.